In a pre-specified 104-week study extension tracking individuals with a baseline body mass index (BMI) of 35 or higher, the weight loss trajectory continued, reaching an average reduction of 30.3%equivalent to 85.0 poundsat the 12-milligram dose
[25] This appraisal is useful context for understanding how similar agents are evaluated in the UK, but it does not apply directly to retatrutide, which remains unlicensed
Diabetes (2017) 66:37284
Given Lillys retatrutide did not reach a weight plateau at the time the Phase 2 study ended, what is the maximum weight loss achievable with longer follow-up
Finally, its important to note that GLP-1 medications are typically taken as an oral or subcutaneously injected medication (like dulaglutide, sold under the brand name Trulicity) in a single daily or weekly dose
Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications